lancl1 Antibody

What is LANCL1 and where is it primarily expressed?

LANCL1 (LanC Lantibiotic Synthetase Component C-Like 1) is a loosely associated peripheral membrane protein related to the LanC family of bacterial proteins . It is highly expressed in the brain, particularly in the cortex, hippocampus, cerebellum, and brainstem . LANCL1 displays primarily cytoplasmic distribution in neurons and other cell types . In addition to neural tissues, LANCL1 is also expressed in other organs, though at lower levels compared to the brain .

What applications are supported by commercially available LANCL1 antibodies?

LANCL1 antibodies are validated for multiple experimental applications:

Most commercially available antibodies show reactivity with human, mouse, and rat samples . When selecting an antibody, consider the specific epitope region, as some antibodies target different amino acid sequences (e.g., AA 349-399, AA 50-150, AA 1-58) .

How should I validate the specificity of a LANCL1 antibody?

To validate LANCL1 antibody specificity:

• Positive controls: Use tissues known to express high levels of LANCL1, such as brain tissue (cortex, hippocampus) .

• Western blot analysis: Confirm a single band at approximately 45 kDa (LANCL1's molecular weight).

• Immunoprecipitation validation: Perform reciprocal co-IP experiments as demonstrated in studies of LANCL1-CBS interactions .

• LANCL1 knockdown: Compare antibody reactivity in wildtype vs. LANCL1 knockdown or knockout samples.

• Subcellular localization: Confirm cytoplasmic distribution pattern in immunofluorescence studies .

When analyzing Western blot data, be aware that LANCL1 can appear as additional bands in some contexts, particularly under oxidative stress conditions .

How can LANCL1 antibodies be used to study oxidative stress responses?

LANCL1 functions as a sensor of oxidative stress and regulator of cellular redox homeostasis . To investigate this role:

• Co-immunoprecipitation studies: Use LANCL1 antibodies to examine interactions with CBS (cystathionine β-synthase) under normal and oxidative stress conditions .

• Comparative analysis: Treat cells with hydrogen peroxide or other oxidative stressors and use LANCL1 antibodies to track changes in protein-protein interactions.

• Subcellular fractionation: Combine with immunoblotting to detect translocation of LANCL1 during oxidative stress.

• Proximity ligation assays: Visualize LANCL1-CBS interactions in situ using LANCL1 antibodies paired with CBS antibodies.

Research has shown that LANCL1 remains bound to CBS under basal conditions but is released when redox balance shifts toward oxidation, enhancing CBS activity to compensate for decreased GSH/GSSG ratio .

What methods are recommended for investigating LANCL1's role in neurodegenerative diseases?

LANCL1 has shown neuroprotective properties in models of neurodegenerative disease:

• Transgenic models: Use LANCL1 antibodies to confirm expression levels in CNS-specific LANCL1 transgenic mice, which show extended lifespan and improved motor performance in ALS models .

• Motor neuron survival analysis: Combine LANCL1 immunostaining with motor neuron markers to assess neuroprotection.

• AKT signaling pathway: Use LANCL1 and phospho-AKT antibodies to investigate how LANCL1 positively regulates AKT activity, a mechanism implicated in its neuroprotective effects .

• Oxidative damage assessment: Pair LANCL1 immunostaining with markers of oxidative damage to correlate LANCL1 levels with neuroprotection.

Results from such approaches have demonstrated that CNS-specific expression of LANCL1 transgene extends lifespan, delays disease onset, and improves motor performance in SOD1 G93A mice (an ALS model) .

How can researchers study LANCL1's interaction with CBS?

The LANCL1-CBS interaction is critical for understanding LANCL1's role in redox homeostasis:

• Co-immunoprecipitation: LANCL1 antibodies can efficiently immunoprecipitate LANCL1 and co-precipitate CBS from mouse cortex and other tissues .

• Recombinant protein studies: Express tagged versions of LANCL1 (e.g., YFP-LANCL1) and CBS (e.g., FLAG-CBS) in HEK293 cells and perform reciprocal co-IP experiments .

• Immunocytochemistry: Use LANCL1 antibodies together with CBS antibodies to demonstrate co-localization in cultured neurons or other cell types .

• Domain mapping: Generate truncated versions of LANCL1 to identify the specific regions involved in CBS binding.

Studies have confirmed that both endogenous and overexpressed LANCL1 and CBS interact, and both proteins display cytoplasmic distribution .

What is known about LANCL1's role in liver tumors and how can antibodies help investigate this?

Recent research has identified LANCL1 as a cell surface protein that promotes liver tumor initiation:

• Immunofluorescence techniques: Use LANCL1 antibodies to confirm membranous localization in hepatocellular carcinoma (HCC) cells .

• FAM49B interaction studies: Employ co-IP with LANCL1 antibodies to study its interaction with FAM49B, a downstream binding partner .

• Ubiquitination analysis: Investigate how LANCL1 prevents FAM49B degradation by blocking its interaction with E3 ubiquitin ligase TRIM21 .

• Therapeutic targeting: Explore using anti-LANCL1 antibodies targeting the extracellular N-terminal domain, which has been shown to suppress self-renewal ability of HCC cells .

The LANCL1-FAM49B axis suppresses Rac1-NADPH oxidase-driven ROS production, which appears independent of LANCL1's glutathione transferase function .

How is LANCL1 involved in neuropathic pain and what experimental approaches are useful?

LANCL1 has been identified as a potential protective factor in neuropathic pain (NeuP):

• Immune cell correlation analysis: Use LANCL1 antibodies in conjunction with T cell markers to investigate the positive correlation between LANCL1 and CD4 naïve T cells (r = 0.880, p < 0.05) .

• miRNA regulation studies: Explore the miR-6325/LANCL1 regulatory axis implicated in neuropathic pain development .

• Immune infiltration analysis: Combine LANCL1 immunostaining with markers for mast cells, macrophages, and T cells to investigate the cascade reactions involved in nerve damage .

• Gene expression analysis: Compare LANCL1 expression levels in different neuropathic pain models to determine its protective effects.

Research suggests that the miR-6325/LANCL1 axis may be involved in the occurrence and development of neuropathic pain, with immune cell infiltration playing a key role .

What are common challenges in LANCL1 detection by Western blot?

Researchers may encounter several challenges when detecting LANCL1 by Western blot:

• Variable expression levels: LANCL1 expression varies significantly between tissues, with highest levels in brain tissue and lower levels in other organs .

• Multiple isoforms: Be aware of potential splice variants or post-translational modifications that may result in multiple bands.

• Cross-reactivity: Some antibodies may cross-react with the related protein LANCL2, which shares 54.2% sequence identity with LANCL1 .

• Extraction methods: LANCL1 is a peripheral membrane protein, so extraction protocols should be optimized to efficiently release it from membranes.

To improve detection:

• Use brain tissue as a positive control

• Try different antibody dilutions (1:5000-1:50000 is recommended for Western blot)

• Include appropriate blocking reagents to minimize background

How can I optimize co-immunoprecipitation experiments with LANCL1 antibodies?

For successful co-IP of LANCL1 and its binding partners:

• Antibody selection: Choose antibodies specifically validated for immunoprecipitation, such as those tested on mouse brain tissue .

• Lysis conditions: Use gentle lysis buffers that preserve protein-protein interactions.

• Cross-linking consideration: For transient interactions, consider using reversible cross-linking reagents.

• Negative controls: Always include non-immune IgG controls to identify non-specific binding .

• Reciprocal co-IP: Confirm interactions by performing co-IP in both directions (e.g., pull down with LANCL1 antibody and detect CBS, then pull down with CBS antibody and detect LANCL1) .

Studies have successfully used LANCL1 antibodies to co-precipitate CBS from mouse cortex and HEK293 cells .

What therapeutic potential does targeting LANCL1 with antibodies hold?

Emerging research suggests several therapeutic applications for LANCL1-targeting antibodies:

• Hepatocellular carcinoma therapy: Anti-LANCL1 antibodies targeting the extracellular N-terminal domain can suppress self-renewal ability of HCC cells .

• Neurodegenerative disease intervention: Based on LANCL1's neuroprotective effects in ALS models, antibodies could be used to monitor treatment efficacy in therapies aimed at upregulating LANCL1 .

• Oxidative stress modulation: LANCL1-targeting approaches might help regulate CBS activity in oxidative stress-related conditions .

• Neuropathic pain management: Given LANCL1's protective role in neuropathic pain, antibody-based monitoring of LANCL1 levels could help in developing treatments .

Further research is needed to fully explore these therapeutic possibilities, particularly regarding antibody specificity, delivery methods, and potential off-target effects.

How might LANCL1 antibodies facilitate research on metabolic regulation?

LANCL1 has been implicated in metabolic processes through its binding to abscisic acid and stimulation of glucose transport :

• Glucose transport studies: LANCL1 antibodies can help monitor protein levels in experiments investigating LANCL1's role in glucose metabolism.

• Receptor function analysis: Antibodies targeting specific LANCL1 domains can help determine which regions are critical for abscisic acid binding.

• Comparative studies with LANCL2: Use specific antibodies to distinguish the roles of LANCL1 versus LANCL2 in metabolic regulation.

• Signaling pathway investigation: Combine LANCL1 immunodetection with analysis of downstream metabolic signaling components.

This research direction is particularly promising given the observed ability of LANCL1 to bind abscisic acid and stimulate glucose transport, indicating potential applications in metabolic disorders .